In The Mood is powered by PT-141, also known as bremelanotide, an FDA-approved peptide that takes a fundamentally different approach to supporting sexual health. Where many traditional options work by targeting blood flow through the vascular system, PT-141 operates upstream—directly activating melanocortin receptors in the brain that regulate sexual arousal and desire. This central nervous system mechanism means it addresses the neurological root of low libido rather than simply managing a physical response.
PT-141 works by binding to melanocortin receptors—specifically MC3R and MC4R—in the hypothalamus, a region of the brain that plays a central role in regulating sexual behavior, mood, and energy. By activating these receptors, PT-141 signals the brain to increase sexual desire and arousal naturally, without relying on hormonal changes or vascular intervention. This makes it a viable option for both men and women experiencing reduced libido, regardless of whether the underlying cause is hormonal, psychological, or situational.
In addition to its primary libido-enhancing effects, PT-141 supports mood regulation and stress reduction through its action on the melanocortin system, which is also involved in the body's broader emotional and energy regulation pathways. Many patients report improved confidence, elevated mood, and increased energy alongside its primary benefits.
At RegenMD, In The Mood is prescribed as a subcutaneous injection administered with a 30G/31G syringe at your individualized dosage. The standard protocol runs Monday through Friday over a four-week program, with dosing personalized to your response and wellness goals. Your provider monitors your progress throughout and adjusts the protocol as needed.
What This Means For You
- Enhanced sexual desire and arousal
- Increased sexual satisfaction and confidence
- Works on the central nervous system, not the vascular system
- Supports mood regulation and stress reduction
- Increased energy levels
- Effective for both men and women
- Personalized dosing monitored by a licensed provider